Total Funding
35
54
Total FundingSeries B raised
Growth Score
-6 pts
Heat Score
-3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
57257
Invirsa develops a molecule that promotes ocular DNA repair and the innate immune response to infection and injury.
- Frank Scardena: Sr. Director and MarketingPast Role: Powermers Inc., President
Robert Shalwitz: Founder and CEOPast Role: Akebia Therapeutics, Chief Medical Officer, Executive Vice President, & Co-Founder
About the Company
Invirsa is developing a unique, broad platform based on a naturally occurring small molecule (INV-102) that has demonstrated enhanced immune response to infection. INV-102 not only reduces viral infection, and potentially bacterial replication, it also reduces inflammation, while enhancing the bodies wound healing response. Invirsa's
technology is first being developed in the ophthalmology and pulmonary space.
Invirsa’s technology has the potential to be a first line therapy for common infectious diseases, whether it's the 100 million viral pulmonary infections or the 5 million infectious conjunctivitis cases that occur every year in the US alone.
